The Use of Statins for Myocardial Death Prevention

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The administration of high dose HMG-CoA reductase inhibitors (Statins) to patients with acute ST-elevation MI (hypoxia/ischemia) who are treated with primary PCI (reoxygenation/ reperfusion) will protect their cardiomyocytes from death and thus preserve LV ejection fraction.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rambam Health Care Campus
• Collaborator: Pfizer
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

1. Patients suffering from acute ST elevation resulting from myocardial infarction, Killip Classification 1 and 2 will be included at-random to either group. Included subjects should be able to give their informed consent to participate in this study.

Exclusion Criteria:

1. The impossibility to give the required informed consent.

2. Known allergy to Atorvastatin.

3. Base line serum creatinine of 1.4 mg/dL.

4. Killip Classification 3 and 4.

5. Persisting vomiting.

6. History of previous liver disease.

7. History of previous muscle disease or rabdomyolisis.

8. Treated already with high dose atorvastatin

9. Non Compliance.